Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Greg Yap - aVenture Research

Greg Yap

AddedMar 31, 2024

UpdatedOct 18, 2026

Greg Yap

Greg Yap

Board Member, Particle Health

Greg Yap's Career

Particle Health

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Series B$39.3MNew York City, NY, US

Board Member· Board

Delfi Diagnostics

Series B$330.5MBaltimore, MD, US

Board Member· Board

H1

Series C$204.1MNew York City, NY, US

Board Member· Board

PyrAmes

Series A$6MCupertino, CA, US

Co-founder

Illumina Ventures

Investment FirmFoster City, CA, US

Entrepreneur in Residence

BlueLight Therapeutics

Series C$46.6MBurlingame, CA, US

Board Member· Board

Co-Founder

People Similar to Greg Yap

Gisela PaulsenBoard Member · Delphi Diagnostics

Lisa MatarBoard Member · Delphi Diagnostics

Winz CasagrandeBoard Member · Delphi Diagnostics

Hansjuergen OverstolzBoard Member · Delphi Diagnostics

Johnsee LeeFounder · Pharus Diagnostics

Krishna YeshwantManaging Partner · GV

Recent news

Finding CEO: It’s the new ‘Finding Nemo’TechCrunch · 2023

Leadership at Particle Health

Jason PrestinarioCEO

Troy BannisterFounder

Similar to Particle Health

1upHealthBoston, MA, USAPI, Healthcareest. 20171upHealthBoston, MA, US · est. 2017

1UpHealth, Inc. provides a healthcare API platform for aggregating and sharing health data across the US.

Series C · $75.5M165

MetriportSan Francisco, CA, USAPI, Medical Dataest. 2022MetriportSan Francisco, CA, US · est. 2022

Metriport: Open-source API for seamless healthcare data integration and management.

Series A · $28.9M7

CarePassportBoston, MA, USPatient Engagementest. 2016CarePassportBoston, MA, US · est. 2016

CarePassport: A global platform enabling patients full access to their medical data.

Seed · $2.1M30

Flow HealthSan Francisco, CA, USHealthcare Platformest. 2014Flow HealthSan Francisco, CA, US · est. 2014

Flow Health: A healthcare tech provider, unifying patient data from all sources for collaborative care.

Seed · $580k750

Leadership at Delfi Diagnostics

Nicholas DracopoliCo-Founder

Victor VelculescuCo-Founder & CEO

Robert B. ScharpfCo-Founder

Alessandro LealCo-Founder

Similar to Delfi Diagnostics

Delphi DiagnosticsHouston, TX, USCancer Diagnosticsest. 2016Delphi DiagnosticsHouston, TX, US · est. 2016

Delphi Diagnostics: Advancing endocrine therapy with gene expression algorithms for breast cancer.

Series A · $470k8

Recent news

H1 Acquires Veda to Solve Healthcare Provider Data ChallengeH1 · 2025

H1 Welcomes Former FDA Commissioner to Board, Acquires Ribbon HealthH1 · 2025

H1 Secures Extension to Series CH1 · 2022

Leadership at H1

Ariel KatzFounder

Zachary FeuersteinCo-Founder

Sylvie VeilleuxBoard Member

Somesh DashBoard Member

Similar to H1

Veeva SystemsPleasanton, CA, USCloud Softwareest. 2007Veeva SystemsPleasanton, CA, US · est. 2007

Veeva Systems: Global cloud software solutions provider

Leadership at PyrAmes

Xina QuanCo-Founder

Zhenan BaoCo-Founder

Peter NoymerBoard Member

Similar to PyrAmes

PraesidiumSt. George, UT, USPatient Monitoringest. 2016PraesidiumSt. George, UT, US · est. 2016

Praesidium offers innovative, non-invasive vital sign monitoring technology.

Series A · $6M17

QuraDuxbury, MA, USMedical Devicesest. 2013QuraDuxbury, MA, US · est. 2013

Qura, Inc. develops wireless implantable sensors for physiological monitoring in healthcare.

Series A · $1M2

Caretaker MedicalCharlottesville, VA, USMedical Devicesest. 2014Caretaker MedicalCharlottesville, VA, US · est. 2014

CareTaker Medical: Innovating ICU-grade wireless devices for remote patient monitoring and blood pressure.

Series B · $10.7M60

Vena VitalsIrvine, CA, USBlood Pressure Monitoringest. 2019Vena VitalsIrvine, CA, US · est. 2019

Vena Vitals: Innovative, cost-effective sticker for continuous blood pressure monitoring.

Seed · $3.9M12

Leadership at Illumina Ventures

Nick NaclerioFounder

Similar to Illumina Ventures

Genomics Investment SyndicateSan Diego, CA, USGenomics Investment SyndicateSan Diego, CA, US

Investing in genomics ventures from seed to late stage.

Investment Firm50

Agilent VenturesPalo Alto, CA, USest. 2000Agilent VenturesPalo Alto, CA, US · est. 2000

Agilent Ventures: A venture capital firm specializing in early-stage investments in tech and life sciences.

Investment Firm50

Bioluminescence VenturesSan Francisco, CA, USest. 2022Bioluminescence VenturesSan Francisco, CA, US · est. 2022

US-based Bioluminescence, a biotech venture firm, invests in transformative science for next-gen medicines, focusing on breakthrough biology, drug discovery, and computational platforms.

Investment Firm7

Solas BioVenturesChattanooga, TN, USest. 2015Solas BioVenturesChattanooga, TN, US · est. 2015

Solas BioVentures: A venture capital firm investing in early-stage health and biopharma companies.

Investment Firm19

Leadership at BlueLight Therapeutics

Joshua SalafskyCo-Founder

Similar to BlueLight Therapeutics

MapLight TherapeuticsPalo Alto, CA, USDrug Discovery, Therapeuticsest. 2018MapLight TherapeuticsPalo Alto, CA, US · est. 2018

Maplight: A biopharmaceutical firm innovating CNS disorder therapeutics via drug discovery platform.

Public · $518.8M67

Ventus TherapeuticsWaltham, MA, USDrug Discoveryest. 2019Ventus TherapeuticsWaltham, MA, US · est. 2019

Ventus pioneers unique, structure-based drug discovery using our ReSOLVE™ platform, advancing new medicines for various diseases.

Series D · $370.1M96

SepternaSan Francisco, CA, USSmall Molecule Drugsest. 2022SepternaSan Francisco, CA, US · est. 2022

Septerna: A biotech firm pioneering novel small molecule medicines for future patient care.

Public · $250M50

Ensem TherapeuticsMedford, MA, USDrug Discoveryest. 2021Ensem TherapeuticsMedford, MA, US · est. 2021

ENSEM Therapeutics: A biotech firm specializing in drug discovery and development for complex oncology targets.

Series A · $77M33

AdelaFoster City, CA, USBlood Testsest. 2020

AdelaFoster City, CA, US · est. 2020

Adela: Innovating accessible technologies for comprehensive cancer detection and management.

Series A · $113M68

Helio HealthIrvine, CA, USCancer Detectionest. 2014Helio HealthIrvine, CA, US · est. 2014

Helio Health: AI-driven healthcare firm commercializing early cancer detection through simple blood tests.

Series B · $148M75

Cleveland DiagnosticsCleveland, OH, USCancer Diagnosticsest. 2013Cleveland DiagnosticsCleveland, OH, US · est. 2013

Cleveland Diagnostics: Innovating high-sensitivity cancer detection for early, curable stages.

Series D · $111M48

AxtriaBerkeley Heights, NJ, US

Consulting, Softwareest. 2010

AxtriaBerkeley Heights, NJ, US · est. 2010

Axtria, Inc.: A US-based big data, AI software, and business consulting service provider.

Late Stage Private · $206.2M3.9k

HumigentIselin, NJ, USest. 2025HumigentIselin, NJ, US · est. 2025

Builds applied AI intelligence and agentic products for pharmaceutical and biotech organizations.

FreshpaintWoerden, Utrecht, NLData Platform, Healthcareest. 2019FreshpaintWoerden, Utrecht, NL · est. 2019

HIPAA-compliant data handling for healthcare marketing.

Series A · $16.1M45